{"id":"https://openalex.org/W2590479218","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.e18062","title":"Combination effects of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) and individual chemotherapeutics in non-small cell lung cancer (NSCLC) cells with and without sensitizing-EGFR mutations.","display_name":"Combination effects of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) and individual chemotherapeutics in non-small cell lung cancer (NSCLC) cells with and without sensitizing-EGFR mutations.","alternate_titles":[],"publication_year":2011,"publication_date":"2011-05-20","ids":{"openalex":"https://openalex.org/W2590479218","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.e18062","mag":"2590479218"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2011.29.15_suppl.e18062","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.e18062","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2011.29.15_suppl.e18062","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2590479218"],"child_works_count":0,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5033809541","display_name":"C. Tsai","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. Tsai","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"K. Chang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K. Chang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018627312","display_name":"Cheryl Hsiang-Ling Chiu","orcid":"https://orcid.org/0000-0002-6946-9785","observed_orcids":["https://orcid.org/0000-0002-6946-9785"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. Chiu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5111593536","display_name":"S. Hsiao","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. Hsiao","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"29","issue":"15_suppl","first_page":"e18062","last_page":"e18062"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.8629999756813049},{"id":"https://openalex.org/keywords/egfr-tyrosine-kinase-inhibitors","display_name":"EGFR tyrosine kinase inhibitors","score":0.9200000166893005},{"id":"https://openalex.org/keywords/gefitinib","display_name":"gefitinib","score":0.9980000257492065},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.7070000171661377},{"id":"https://openalex.org/keywords/drug-interactions","display_name":"drug interactions","score":0.5709999799728394},{"id":"https://openalex.org/keywords/combination-index","display_name":"combination index","score":0.5789999961853027},{"id":"https://openalex.org/keywords/synergistic-effect","display_name":"synergistic effect","score":0.4950000047683716},{"id":"https://openalex.org/keywords/antagonism","display_name":"antagonism","score":0.9729999899864197},{"id":"https://openalex.org/keywords/cisplatin","display_name":"cisplatin","score":0.9110000133514404},{"id":"https://openalex.org/keywords/gemcitabine","display_name":"gemcitabine","score":0.9940000176429749},{"id":"https://openalex.org/keywords/pemetrexed","display_name":"pemetrexed","score":0.9990000128746033},{"id":"https://openalex.org/keywords/paclitaxel","display_name":"paclitaxel","score":0.9940000176429749},{"id":"https://openalex.org/keywords/docetaxel","display_name":"docetaxel","score":0.996999979019165},{"id":"https://openalex.org/keywords/vinorelbine","display_name":"vinorelbine","score":1.0}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7496737837791443},{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.6641664505004883},{"id":"https://openalex.org/C2780258809","wikidata":"https://www.wikidata.org/wiki/Q414143","display_name":"Gemcitabine","level":3,"score":0.616879940032959},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.580162763595581},{"id":"https://openalex.org/C2777292972","wikidata":"https://www.wikidata.org/wiki/Q423762","display_name":"Paclitaxel","level":3,"score":0.5747712254524231},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.5387324690818787},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.5298055410385132},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.4776524305343628},{"id":"https://openalex.org/C2781190966","wikidata":"https://www.wikidata.org/wiki/Q420436","display_name":"Docetaxel","level":3,"score":0.45118504762649536},{"id":"https://openalex.org/C2780783641","wikidata":"https://www.wikidata.org/wiki/Q738686","display_name":"MTT assay","level":3,"score":0.45072296261787415},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.4284367859363556},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.42158299684524536},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4117785096168518},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3703545928001404},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.35488057136535645},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.335206538438797},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3226674795150757},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3122982978820801},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.22356274724006653},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2011.29.15_suppl.e18062","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.e18062","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2011.29.15_suppl.e18062","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9763000011444092,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2035711564","https://openalex.org/W1990031106","https://openalex.org/W2123555204","https://openalex.org/W2170830310","https://openalex.org/W2808941203","https://openalex.org/W2078523315","https://openalex.org/W1987321907","https://openalex.org/W2096775149","https://openalex.org/W2067810310","https://openalex.org/W2086913687"],"abstract_inverted_index":{"e18062":[0],"Background:":[1],"NSCLC":[2,30,77,259],"cells":[3,251,260,288],"harboring":[4,73,261],"sensitizing-EGFR":[5,74,229,262],"mutations":[6,263],"are":[7],"supposed":[8],"to":[9,13],"be":[10],"more":[11],"sensitive":[12],"the":[14,35,39,45,87,118,159,180,183,228,233,278,291],"combination":[15,46,122,204,234],"of":[16,48,70,90,99,103,108,112,121,150,158,182,206,217,273,285,294],"EGFR-TKI":[17,265],"and":[18,38,64,115,143,156,174,199,208,248,266,281],"chemotherapy":[19],"than":[20],"EGFR":[21],"wild":[22],"type":[23],"cells.":[24],"We":[25,275],"tested":[26],"this":[27],"theory":[28],"in":[29,67,80,227,250,290],"cell":[31,78,91,186],"lines.":[32],"Methods:":[33],"Using":[34],"MTT":[36],"assay":[37],"classical":[40],"isobole":[41],"method,":[42],"we":[43],"examined":[44],"effects":[47,205,235],"six":[49],"gefitinib":[50,207,279],"(G)-containing":[51],"doublets,":[52],"namely,":[53],"G/C":[54],"(cisplatin),":[55],"G/Gem":[56],"(gemcitabine),":[57],"G/Pem":[58],"(pemetrexed),":[59],"G/P":[60],"(paclitaxel),":[61],"G/D":[62,114,155,247],"(docetaxel)":[63],"G/V":[65,157],"(vinorelbine)":[66],"a":[68,81,215,270],"panel":[69],"15":[71],"(3":[72],"mutations)":[75],"chemonaive":[76],"lines,":[79,92],"concomitant":[82],"administration":[83],"schedule.":[84],"Results:":[85],"In":[86,178,231],"whole":[88],"group":[89],"overall":[93],"results":[94],"showed":[95,220,269],"marked":[96,110,237],"antagonism":[97,224],"(ant)":[98],"G/C,":[100,151],"additivism":[101],"(add)":[102],"G/Gem,":[104,152],"marginal":[105],"synergism":[106],"(syn)":[107],"G/P,":[109,154,246],"syn":[111,244],"G/Pem,":[113,153],"G/V,":[116],"with":[117,252,264],"mean":[119],"values":[120],"index":[123],"(mCIs)":[124],"were":[125,163,188,236],"1.184":[126],"(95%":[127],"confidence":[128],"interval:":[129],"1.12-1.24,":[130],"P=0.001),":[131],"1.027":[132],"(0.948-1.107,":[133],"P=0.683),":[134],"0.911(0.833-0.989,":[135],"P=0.078),":[136],"0.814":[137],"(0.7-0.92,":[138],"P=0.011),":[139],"0.870":[140],"(0.78-0.96,":[141],"P=0.017),":[142],"0.899":[144],"(0.816-0.982,":[145],"P=0.041),":[146],"respectively.":[147,177,202],"The":[148,203],"mCIs":[149,181],"3":[160],"sensitizing":[161,254],"mutants":[162],"1.116":[164],"(ant),":[165,167,171,173,176,190],"1.110":[166],"0.993":[168],"(add),":[169,192],"1.077":[170],"1.067":[172],"1.082":[175],"contrast,":[179,232],"other":[184],"12":[185],"lines":[187],"1.201":[189],"1.007":[191],"0.769":[193],"(syn),":[194,196,198,201],"0.869":[195],"0.820":[197],"0.853":[200],"single":[209],"chemotherapeutic":[210],"agents":[211],"that":[212,277],"act":[213],"through":[214],"variety":[216],"anti-cancer":[218],"mechanisms":[219],"consistent":[221],"low":[222],"degree":[223],"(G/Pem,":[225,245],"additivism)":[226],"mutants.":[230],"ant":[238],"(G/C),":[239],"add":[240],"(G/Gem),":[241],"or":[242],"obvious":[243],"G/V)":[249],"no":[253],"mutations.":[255],"Conclusions:":[256],"Concomitantly":[257],"treated":[258],"individual":[267],"chemotherapeutics":[268],"broad":[271,292],"spectrum":[272,293],"antagonism.":[274],"hypothesize":[276],"hypersensitivity":[280],"associated":[282],"oncogenic":[283],"shock":[284],"these":[286],"mutant":[287],"resulted":[289],"chemo-refractoriness.":[295]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2590479218","counts_by_year":[],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2017-03-03T00:00:00"}
